| Revision as of 22:51, 4 May 2015 editHernando1620 (talk | contribs)8 edits this page was updated to reflect the current as of 2015. Both the CEO / CFO and Chairman of the Board are updated as well as the description of the company. The previous information was outdated (2005) and doesn't reflect the current state of company.← Previous edit | Revision as of 22:52, 4 May 2015 edit undoHernando1620 (talk | contribs)8 edits Updated the number of employess as of 2015Next edit → | ||
| Line 9: | Line 9: | ||
| location = ], ], ] | | location = ], ], ] | | ||
| key_people = ], Chairman <br />], CEO/President | | key_people = ], Chairman <br />], CEO/President | | ||
| num_employees = |
num_employees = 95 (2015) | | ||
| industry = ]| | industry = ]| | ||
| homepage = | | homepage = | | ||
Revision as of 22:52, 4 May 2015
 | This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Neurocrine Biosciences" – news · newspapers · books · scholar · JSTOR (February 2008) (Learn how and when to remove this message) |
| Neurocrine logo | |
| Company type | Public Nasdaq: NBIX |
|---|---|
| Industry | Biotechnology |
| Founded | 1992 |
| Headquarters | San Diego, California, U.S. |
| Key people | Bill Rastetter, Chairman Kevin Gorman, CEO/President |
| Number of employees | 95 (2015) |
| Website | www.neurocrine.com |
Neurocrine Biosciences Neurocrine Biosciences, Inc. of San Diego discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.
RESEARCH AND DEVELOPMENT PROGRAMS
Neurocrine’s Research Group continues to advance novel small molecule compounds into clinical development. Neurocrine scientists are focusing on developing small molecule antagonists against G-protein coupled receptors. Our scientists possess the skills and experience necessary to bring compounds from basic research concepts to drug candidate stage. Neurocrine utilizes advanced technologies to enhance its drug discovery capabilities and to accelerate the drug development process. Working together, Neurocrine’s chemists, pharmacologists and biologists strive to create new solutions to unmet medical problems.
References
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Misplaced Pages by expanding it. |